Acute myeloid leukemia: A rare cause of acquired isolated factor VII deficiency

IF 0.7 Q4 HEMATOLOGY
Zaineb Mlayah, Haifa Hafsa, Alaa Ghorbel, Nader Slama, Sara Boukhris, Mohamed-Adnene Laatiri
{"title":"Acute myeloid leukemia: A rare cause of acquired isolated factor VII deficiency","authors":"Zaineb Mlayah,&nbsp;Haifa Hafsa,&nbsp;Alaa Ghorbel,&nbsp;Nader Slama,&nbsp;Sara Boukhris,&nbsp;Mohamed-Adnene Laatiri","doi":"10.1016/j.lrr.2025.100516","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Acquired factor VII deficiency remains a rare pathology. Only 5 prior reported cases of aFVIID associated with acute myeloid leukemia (AML) have been described in the literature. Despite the rarity of these occurrences, these cases hold significant clinical and scientific implications given the need to understand the physopathology and to establish a therapeutic protocol ensuring better management.</div></div><div><h3>Case presentation</h3><div>A 38-year-old Arab male with AML was diagnosed at our Department of Clinical Hematology. The initial coagulation panel at admission revealed slightly low prothrombin ratio (PT) of 56 %, while the international normalized ratio (INR) and partial thromboplastin time (PTT) were within normal. Prothrombin complex coagulation factor dosing (PCCFD) confirmed an isolated reduction in the FVII in repeated samples, indicating an isolated deficiency. This patient did not present severe bleeding syndrome and had received conventional chemotherapy (cytarabine (Cytarabine)+ idarubicin). The evolution was marked by cytological remission (CR) with correction of coagulation disorders.</div></div><div><h3>Conclusion</h3><div>In conclusion, the intricate relationship between isolated aFVIID and AML remains mysterious. Researchers are essential to unravel the intricacies of this rare hematological condition. Further exploration into the molecular mechanisms, prognostic implications, and evolving treatment modalities is crucial to enhance the precision and efficacy of therapeutic interventions.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100516"},"PeriodicalIF":0.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213048925000184","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Acquired factor VII deficiency remains a rare pathology. Only 5 prior reported cases of aFVIID associated with acute myeloid leukemia (AML) have been described in the literature. Despite the rarity of these occurrences, these cases hold significant clinical and scientific implications given the need to understand the physopathology and to establish a therapeutic protocol ensuring better management.

Case presentation

A 38-year-old Arab male with AML was diagnosed at our Department of Clinical Hematology. The initial coagulation panel at admission revealed slightly low prothrombin ratio (PT) of 56 %, while the international normalized ratio (INR) and partial thromboplastin time (PTT) were within normal. Prothrombin complex coagulation factor dosing (PCCFD) confirmed an isolated reduction in the FVII in repeated samples, indicating an isolated deficiency. This patient did not present severe bleeding syndrome and had received conventional chemotherapy (cytarabine (Cytarabine)+ idarubicin). The evolution was marked by cytological remission (CR) with correction of coagulation disorders.

Conclusion

In conclusion, the intricate relationship between isolated aFVIID and AML remains mysterious. Researchers are essential to unravel the intricacies of this rare hematological condition. Further exploration into the molecular mechanisms, prognostic implications, and evolving treatment modalities is crucial to enhance the precision and efficacy of therapeutic interventions.
急性髓性白血病:获得性分离因子VII缺乏的罕见原因
背景:获得性因子VII缺乏仍然是一种罕见的病理。文献中仅报道了5例与急性髓系白血病(AML)相关的aFVIID病例。尽管这些病例很少发生,但这些病例具有重要的临床和科学意义,因为需要了解生理病理并建立治疗方案以确保更好的管理。病例介绍:一位38岁的阿拉伯男性在我临床血液科确诊为急性髓性白血病。入院时的初始凝血结果显示凝血酶原比率(PT)略低,为56%,而国际标准化比率(INR)和部分凝血活素时间(PTT)在正常范围内。凝血酶原复合物凝血因子剂量(PCCFD)在重复样品中证实了FVII的分离减少,表明分离缺陷。该患者未出现严重出血综合征,并接受了常规化疗(阿糖胞苷(阿糖胞苷)+阿达柔比星)。进化的标志是细胞学缓解(CR)和凝血障碍的纠正。结论分离的aFVIID与AML之间的复杂关系仍然是一个谜。研究人员必须解开这种罕见血液学疾病的复杂性。进一步探索分子机制、预后影响和不断发展的治疗方式对于提高治疗干预的准确性和有效性至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Leukemia Research Reports
Leukemia Research Reports Medicine-Oncology
CiteScore
1.70
自引率
0.00%
发文量
70
审稿时长
23 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信